Cargando…

Local therapy in patients with metastatic prostate cancer: a new standard of care?

Detalles Bibliográficos
Autores principales:	Harper, Benjamin, Klaassen, Zachary, Wallis, Christopher J. D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2019
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798034/ https://www.ncbi.nlm.nih.gov/pubmed/35117138 http://dx.doi.org/10.21037/tcr.2019.05.27

Ejemplares similares

Androgen deprivation therapy and Gleason grade: unravelling implications on survival
por: Scott, Michael, et al.
Publicado: (2019)

Decreasing incidence of venous thromboembolic events after radical cystectomy: are we finally improving?
por: Harper, Benjamin T., et al.
Publicado: (2018)

Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2021)

Addressing Mental Health in Urology Patients: The Time is Now
por: Klaassen, Zachary, et al.
Publicado: (2020)

Prostate radiotherapy for metastatic hormone sensitive prostate cancer—myth or reality?
por: Onal, Cem
Publicado: (2019)

Clinical utility of the nuclear-localized AR-V7 biomarker for treatment choice in metastatic castration-resistant prostate cancer
por: Vlaeminck-Guillem, Virginie
Publicado: (2020)

Prostate cancer and hypofractionation: really a new standard of care?
por: Carrie, Christian, et al.
Publicado: (2016)

Metastasis-directed therapy: a new standard for oligorecurrent prostate cancer?
por: Zilli, Thomas, et al.
Publicado: (2018)

Metastatic Hormone-sensitive Prostate Cancer: Current Perspective on the Evolving Therapeutic Landscape
por: Hall, Mary E, et al.
Publicado: (2020)

Implications of local failure on overall prognosis in aggressive prostate cancer
por: Mula-Hussain, Layth, et al.
Publicado: (2020)

Consensus on the Screening, Staging, Treatment, and Surveillance of Localized, Recurrent, and Metastatic Prostate Cancer: The First Global Prostate Cancer Consensus Conference for Developing Countries
por: Maluf, Fernando Cotait, et al.
Publicado: (2021)

Will chemoradiation-based bladder-sparing therapy become a standard of care for muscle-invasive bladder cancer?
por: Koga, Fumitaka
Publicado: (2020)

Local staging of prostate cancer with imaging: can hybrid imaging be the solution?
por: Turkbey, Baris
Publicado: (2020)

Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta?
por: Elias, Roy, et al.
Publicado: (2023)

The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma
por: Rathi, Nityam, et al.
Publicado: (2019)

New classification may assist the development of targeted therapies for treatment-refractory castration-resistant prostate cancer
por: Lin, Ching-Yu, et al.
Publicado: (2020)

PIVOT and the challenges of localized prostate cancer care
por: Weinberg, Aviva E., et al.
Publicado: (2012)

New standard in locally advanced rectal cancer
por: Solé, Sebastián, et al.
Publicado: (2020)

Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy?
por: Peinetti, Nahuel, et al.
Publicado: (2022)

PSMA theragnostics for metastatic castration resistant prostate cancer
por: Song, Hong, et al.
Publicado: (2022)

Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation‐based therapy
por: Turco, Fabio, et al.
Publicado: (2022)

Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care
por: Mittal, Abhenil, et al.
Publicado: (2023)

Assessing patient risk from cancer and COVID-19: Managing patient distress
por: Klaassen, Zachary, et al.
Publicado: (2021)

Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer
por: Maltoni, Roberta, et al.
Publicado: (2022)

New insights for drug resistance in metastatic castration-resistant prostate cancer
por: Kushwaha, Prem Prakash, et al.
Publicado: (2022)

Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate Cancer
por: Gleicher, Stephanie, et al.
Publicado: (2021)

Standards and standard-compliance
por: Sterk, Peter
Publicado: (2009)

Early serial circulating tumor DNA sequencing predicts the efficacy of chemohormonal therapy in patients with metastatic hormone-sensitive prostate cancer
por: Du, Xinxing, et al.
Publicado: (2023)

Behind a personalized therapy with immune check-point inhibitors in metastatic bladder cancer: ready for a primetime?
por: Poletajew, Sławomir, et al.
Publicado: (2020)

Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?
por: Travert, Camille, et al.
Publicado: (2020)

Quantification and Optimization of Standard-of-Care Therapy to Delay the Emergence of Resistant Bone Metastatic Prostate Cancer
por: Araujo, Arturo, et al.
Publicado: (2021)

What Is New in the Management of High-Risk Localized Prostate Cancer?
por: Wani, Mudassir, et al.
Publicado: (2023)

Elevated suicide risk among patients with urologic malignancies: highlighting at-risk populations
por: Sayyid, Rashid K., et al.
Publicado: (2020)

Surgery vs. radiotherapy in localized prostate cancer. Which is best?
por: Welz, Stefan, et al.
Publicado: (2008)

Effects of androgen deprivation therapy duration and Gleason grade on survival outcomes of high risk prostate cancer
por: Kim, Do Kyung, et al.
Publicado: (2019)

Commentary: Transcatheter therapies for tricuspid regurgitation: The rise of a new standard?
por: Faroux, Laurent, et al.
Publicado: (2020)

The Management of Metastatic Castrate-Sensitive Prostate Cancer: From Guidelines to Real-World Practice
por: Gebrael, Georges, et al.
Publicado: (2023)

Androgen receptor splice variant 7 in castration resistant prostate cancer treated with hormonal therapy: what is in the pipeline?
por: Chirra, Martina, et al.
Publicado: (2019)

Radiotherapy to the Primary Tumor: The First Step of a Tailored Therapy in Metastatic Prostate Cancer
por: Ferro, Matteo, et al.
Publicado: (2022)

Oncolytic immunotherapy for metastatic cancer: lessons and future strategies
por: Guo, Zong-Sheng
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v8kljq0vcsf3u8di3t1nratsie